Lataa...
Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice
Prasugrel and ticagrelor are two novel promising antiplatelet agents inhibiting the platelet activation via the adenosine diphosphate pathway. Both achieve a faster, more intense, and more consistent platelet inhibition than clopidogrel. Both novel antiplatelet agents have demonstrated superiority o...
Tallennettuna:
| Julkaisussa: | Interv Cardiol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Radcliffe Cardiology
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5844017/ https://ncbi.nlm.nih.gov/pubmed/29588796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/icr.2014.9.3.164 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|